Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1

Sponsor
Hospital Universitari Vall d'Hebron Research Institute (Other)
Overall Status
Completed
CT.gov ID
NCT02931071
Collaborator
CIEMAT (Other), CIBERER (Other)
13
2
1
61
6.5
0.1

Study Details

Study Description

Brief Summary

Fanconi anemia (FA) is a congenital disease characterized by bone marrow failure and increased incidence of malignant tumors. The Project pursue the optimization of the collection of hematopoietic progenitor cells for later use in another clinical trial entitled "Clinical Trial Phase I/II to evaluate the safety and efficacy of the infusion of autologous CD34+ cells mobilized with mozobil and filgrastim, and transduced with a lentiviral vector carrying the FANCA gene (Orphan Drug) for patients with Fanconi Anemia Subtype A ". The objectives of this study are, therefore, to assess the safety and efficacy of CD34+ cells mobilization with mozobil and filgrastim, which is postulated the most efficient for the collection of CD34+ cells from FA patients.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
13 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Clinical Phase II Trial to Evaluate Efficacy and Safety of CD34+ Cells Mobilization and Collection After Treatment With Plerixafor and Filgrastim in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene and Reinfusion in the Patient
Study Start Date :
Sep 1, 2013
Actual Primary Completion Date :
Oct 1, 2018
Actual Study Completion Date :
Oct 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: plerixafor and filgrastim treatment

to assess the safety and efficacy of CD34+ cells mobilization with plerixafor and filgrastim

Drug: filgrastim
G-CSF (12 μg/Kg/12 h) 8 days.

Drug: plerixafor
Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor

Outcome Measures

Primary Outcome Measures

  1. Toxicity of the mobilization procedure according to National Cancer Institute (CTC NCI, versión 3.0) [after 12 months]

    At a year (± 30 days) after the last apheresis, a complete physical examination, blood cell count, basic biochemistry and bone marrow aspirate will be done to the patient in order to control their general health status.

Secondary Outcome Measures

  1. Percentage of patients that reach >5 CD34+ cells/mcl after treatment with filgrastim and plerixafor [after 8 days]

    mobilization protocol will be determined by the percentage of patients who achieve peripheral blood counts exceeding 5 CD34+ cells /microliter

  2. Percentage of patients that reach a total CD34+ yield >4x10E6/kg, using the estimated weight of the patient in 5 years [after 8 days]

    the CD34+ cell collection protocol will be determined by the percentage of patients who reach at least one million CD34 + cells per kilogram of body weight projected to 5 years after the mobilization process

  3. Percentage of samples in which the recovery of CD34+ cells after the immunomagnetic selection procedure is >50% [after 8 days]

    the of CD34+ cell selection process will be determined by the proportion of immunoselected samples where the recovery of CD34 + cells is at least 50%, and where the final percentage of CD34+ cells is at least 50%

  4. Percentage of patients in which the CD34+ cells after the immunomagnetic selection is ³ 4x10E6/kg, using the projected weight at 5 years [after 8 days]

    will be determined by the percentage of patients who reach at least one million CD34 + cells per kilo of weight projected to 5 years after the immunomagnetic selection process of all the collected cells

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 64 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female > 1 year

  • diagnosed of Fanconi's anemia confirmed by instability chromosomal test with diepoxy-butane or mitomycin C

  • At least one of the following parameters must be higher than these values: Hemoglobin:8,0 g/dL; neutrophils: 750/mm3; platelets: 30.000/mm3

  • Lansky index> 60%.

  • Left ventricular ejection fraction >50%.

  • To grant informed consent in agreement with current law norms

  • Women in childbearing age must obtain a negative result in the pregnancy test in serum or urine in the visit of selection and accept the use of suitable contraceptive methods since at least 14 days prior to the first dose of mobilizing treatment until the 14 days following the last

Exclusion Criteria:
  • Evidence of myelodysplastic syndromes or leukemia, or cytogenetic abnormalities predicted of these syndromes in bone marrow aspiration. Cytogenetic analyses performed 2 months before starting study are accepted

  • Patients with active infection process or any other underlaying severe medical process

  • Severe Functional alteration of organs (hepatic, renal, respiratory)(?3), according to National Cancer Institute (NCI CTCAE v3) criteria

  • Haematopoietic transplant

  • Any disease or concomitant process that is not compatible with the study as per investigator opinion

  • Patients not elegible because of an psico-social evaluation

  • Patients that received transfusional support during the last 3 months.

  • Pregnant or breastfeeding women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Universitari Vall d'Hebron Barcelona Spain 08035
2 Hospital Infantil Universitario Niño Jesus Madrid Spain 28009

Sponsors and Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute
  • CIEMAT
  • CIBERER

Investigators

  • Principal Investigator: Cristina Díaz de Heredia, MD, PhD, Hospital Vall d'Hebron

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospital Universitari Vall d'Hebron Research Institute
ClinicalTrials.gov Identifier:
NCT02931071
Other Study ID Numbers:
  • FANCOSTEM-1
  • 2011-006197-88
First Posted:
Oct 12, 2016
Last Update Posted:
May 27, 2020
Last Verified:
May 1, 2020
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 27, 2020